Koppers Is Asking Investors to Believe in January 1 — For the Third Year Running
A guidance cut, a record cash-flow year and an accelerated exit from Stickney all point at one question: is 2027 a genuine reset or the same promise in a new jacket?
KOP · Earnings Call · 2026-11-06
More volume, less profit, and a familiar culprit
Koppers sold 3% more in the third quarter and earned 18% less. Revenue of $499 million produced $58 million of adjusted EBITDA against $72 million a year earlier, taking the margin from 14.6% to 11.6% and adjusted EPS from $1.21 to $0.77. Management put a number on it: “we estimate the year over year impact of higher input costs to be $16 million in the third quarter” — Eric Brenner, Unknown · 2026-11-06. Full-year adjusted EBITDA guidance came down to $220–225 million and EPS to $3.10–3.25.
The mechanism is not mysterious, and Leroy Ball described it plainly: “costs for coal tar, copper, diesel, freight and other raw materials continue to rise and move through our businesses faster than we could recover them through pricing or cost reductions in other areas” — Leroy Ball Jr., Chief Executive Officer · 2026-11-06. That is the whole quarter. input cost inflation, higher raw material pricing, and logistics cost all sit at the top of this quarter's keyword stack — as they did last quarter, and the quarter before that. Tar alone rose 30% year over year, pushed by the same Middle East Conflict and Chinese mine closures that chemicals peers from Cabot to Tronox are citing. Koppers' problem is not idiosyncratic; its exposure to it is.
The real change is where the cost lands. Carbon Materials & Chemicals — the segment that has been shrinking for years — posted $6 million of EBITDA, down 61%, absorbing $9 million of the raw-material hit. Performance Chemicals, the crown jewel, still grew EBITDA $4 million to $30 million on 10% volume. The portfolio is behaving exactly as designed; the commodity tail is what bit.
Record cash flow, from the right and the wrong pockets
While earnings fell, the cash statement went the other way. Nine-month operating cash flow of $127 million and free cash flow of $92 million are both records, and the full-year free cash flow guide was raised to $115–135 million. The board lifted the dividend 12.5% to $0.09 a quarter, or $0.36 annualized.
That is not entirely repeatable. Some of the improvement came from $12 million of working capital release and roughly $14 million of lower pension funding, plus liquidation of byproduct inventory as Stickney winds down. But the structural part is real: capital expenditure of $12 million in the last filed quarter, down more than half from the 2022 peak, with management now framing $40–45 million as the ongoing run rate. “something in the $40 million to $45 million range would be more of the ongoing capital requirements within our businesses” — Leroy Ball Jr., Chief Executive Officer · 2026-11-06, Ball said. A business that used to spend $100 million to stand still now converts most of its EBITDA into cash.
Over the next 3 years, at the pace that we have talked about, which we have not moved off of, at least $100 million a year — we will generate over the next 3 years free cash flow that will represent close to half of our market cap.
At a $567 million market cap, that arithmetic is roughly right: 6.7x trailing free cash flow, or nearer 4.5x on the midpoint of this year's guide. Against that, net cash of negative $870 million and 3.7x net leverage, versus a stated 2–3x target.
Two things that genuinely did change
First, Stickney. In May, asked whether the plant would drop to a single column, Ball said “there is a high likelihood that we will be heading in that direction” — Leroy Ball, Chief Executive Officer · 2026-02-26. Six months later the answer is starker: distillation stopped September 30, and remaining chemical production ceased in October. The full closure is worth $15–20 million of annual EBITDA and $1.00–1.20 of EPS, and it retires the fixed cost and capital drag that has made that segment a chronic value leak.
Second, and less cheerfully, rail. Koppers gave price concessions to Class 1 customers to win volume — a new entry in the language of this call, and a reversal. “it was a conscious decision to secure the volumes so that we could plan and execute our network optimization” — Eric Brenner, Unknown · 2026-11-06, CFO Eric Brenner said. RUPS EBITDA fell to $22 million from $29 million as a result. This is the uncomfortable bit. Heading into 2025, management's rail story was that pricing recovery had run its course: “I think we've maximized all we are going to be able to do at this point on that until we have some contracts expiring” — Leroy Mangus Ball, Chief Executive Officer (CEO) · 2025-08-08. Handing price back to hold throughput is a different kind of admission.
The calendar is the thesis
The bull case rests entirely on a date. Roughly 80% of Performance Chemicals' two-year book is already repriced for January 1, 2027 — “over 80% of our booked business have come to agreement” — Leroy Ball Jr., Chief Executive Officer · 2026-11-06 — with the remainder expected in weeks. That is structurally credible: it is the same two-year contract cycle that let Koppers pass through over $500 million of pricing across 2022–2023 after being caught flat-footed.
But the pattern is now three years old. In February, Ball was explicit that the company could not grow share and price simultaneously: “we are not growing market share and improving price in 2026. That is not happening” — Leroy Ball, Chief Executive Officer · 2026-02-26. In May, guidance came down $10 million for oil. Now it has come down again for tar, freight and diesel. And the PC engine underneath — the Performance Chemicals franchise — remains hostage to a residential market Ball concedes is flat to negative, with industrial demand repeatedly described as helpful but not a needle mover.
What the market is being asked to underwrite is that a smaller, less capital-hungry Koppers, with $42 million of Catalyst transformation benefits banked year-to-date, a network optimization that finally retired Stickney, and a January price reset on the majority of its book, sees EBITDA snap back while leverage falls from both ends. A $180 million operating loss in that quarter is the accounting version of the same decision.
The bear case is simpler and has better precedent: the contract-timing asymmetry that management blames for 2026 is a permanent feature of its business model, and each year the recovery gets promised to the next calendar. The stock is down more than a quarter from its 2024 peak and has given back most of its recent run, so investors are already skeptical. The tell will not be the January price letters — those are nearly done. It will be whether second-quarter 2027 margins arrive in Performance Chemicals' normal range, and whether the 3.7x leverage number actually moves. Until then this is cash generation at a deep discount to a promise about next year.